Search clinical trials for: Muc1,CLL1, CD33, CD38, CD56, and/or CD123

Total 370 results

Shenzhen Geno-Immune Medical Institute
Yunnan Cancer Hospital; Zhujiang Hospital, Southern Medical University, Guangzhou...

Unknown

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhujiang Hospital
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Relapsed/Refractory Acute Myeloid Leukemia(AML)

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal CAR-T Cells Targeting AML

Acute Myeloid Leukemia

China
Guangzhou Bio-gene Technology Co., Ltd

Withdrawn

Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

AML

China
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
Assiut University

Unknown

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Immune Thrombocytopenia
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
920th Hospital of Joint Logistics Support Force...
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

Acute Myeloid Leukemia

China
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML (BAH244)

Acute Myeloid Leukemia | AML | AML, Adult | AML, Adult Recurrent

China
Molecular Partners AG

Recruiting

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Leukemia | Acute | Relapsed | Myeloid

Netherlands, France, Lithuania, Switzerland
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-T Therapy Post CD19-targeted Immunotherapy

CD19 Negative B-cell Malignancies

China
Wuxi People's Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Beijing Boren Hospital

Recruiting

Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhujiang Hospital
The Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)

Relapsed/Refractory Multiple Myeloma(MM)

China
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Zhejiang University
Hangzhou Qihanjiyin Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

AML, Adult

China
Xinqiao Hospital of Chongqing
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Bayer

Completed

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

Breast Neoplasms | Breast Cancer, Metastatic

France, Germany, Spain, Austria, Belgium, Slovenia, Poland, Bulgaria, United Kingdom, Italy
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Asmaa Hassan mohamed Abdel Mawjoud

Recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Hematologic Malignancies

Egypt
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
The First Affiliated Hospital of Soochow University

Recruiting

Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Beijing Doing Biomedical Co., Ltd.

Unknown

Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.

Gastric Cancer

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
The Affiliated Hospital of the Chinese Academy...
Chinese PLA General Hospital

Unknown

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

Relapsed and/or Refractory CD33+ AML

China
Southwest Hospital, China

Unknown

A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies

Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Assiut University

Unknown

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia
St. Jude Children's Research Hospital

Active, not recruiting

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

B-ALL | T-ALL | AML/MDS | BPDCN

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Malignant Glioma of Brain | Gastric Carcinoma | Colorectal Carcinoma

China
Guangzhou Bio-gene Technology Co., Ltd

Not yet recruiting

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Acute Myeloid Leukemia | Leukemia
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

NK-Cell Leukemia | Extranodal NK T Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Acute Myeloid Leukemia | Acute Myelogenous Leukemia | Acute Myeloid Leukemia With Maturation | Acute Myeloid Leukemia Without Maturation | ANLL

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); MacroGenics

Recruiting

Post-transplant Flotetuzumab for AML

Leukemia, Myeloid, Acute

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Y-mAbs Therapeutics
Children's Oncology Group

Terminated

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Childhood

United States
Hamilton Health Sciences Corporation
McMaster University

Completed

A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 (MUC1)

Prostate Cancer

Canada
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China

Search clinical trials for: Muc1,CLL1, CD33, CD38, CD56, and/or CD123

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations